AKT1 and acute myeloid leukemia: Critically, its ability to inhibit AKT signaling (Sathishkumar and Sathuvan, 2025) aligns with the therapeutic needs of FLT3-mutated AML, where constitutive PI3K/AKT activation promotes chemoresistance (Kurosu et al., 2013).